Please assess the completion status of the following clinical trial:

Trial Title: 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive, newly diagnosed or previously untreated POAG patients~* Patients with typical glaucomatous disc, or visual field damage~* Patient must have IOP (at 10:00 ± 1 hour)greater than 25 mm Hg~Exclusion Criteria:~* Uncontrolled glaucoma~* Distance best corrected Snellen visual acuity worse than 1/10~* Contraindications to brimonidine or dorzolamide and β-blockers~* History of lack of response (\<10% morning IOP reduction) to any medication~* Patient can not understand the instructions and adhere to medications~* Patient is a female of childbearing potential or lactating mother~* Prior surgery, past use of steroids (within 2 months)~* Severe dry eyes and use of contact lenses~* History of non-adherence~* Patients with closed angles

- Gender: ALL
- Minimum Age: 29 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Drug: Dorzolamide/Timolol (Type: ACTIVE_COMPARATOR): None
- Treatment with Brimonidine/Timolol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).